Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Robert Hassan El Maraghi
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Pascal Hammel
Consultant or Advisory Role - Celgene
Volker Heinemann
Consultant or Advisory Role - Amgen; Celgene; Merck; Roche
Honoraria - Amgen; Celgene; Merck; Roche
Research Funding - Amgen; Celgene; Merck; Roche
Volker Kunzmann
Consultant or Advisory Role - Celgene
Javier Sastre
No relevant relationships to disclose
Werner Scheithauer
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Genomic Health; Roche; Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Onyx; Pfizer; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Luis Teixeira
No relevant relationships to disclose
Giampaolo Tortora
Research Funding - Celgene
Jean-Luc Van Laethem
No relevant relationships to disclose
Rosemary Young
No relevant relationships to disclose
Xinyu Wei
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Brian Lu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Alfredo Romano
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene